サンプル依頼リスト カート
  • English
  • Korean
表紙：薬剤耐性てんかんの世界市場-2023年～2030年
市場調査レポート
商品コード
1345447

薬剤耐性てんかんの世界市場-2023年～2030年

Global Drug-Resistant Epilepsy Market - 2023-2030

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
薬剤耐性てんかんの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

薬剤耐性てんかんの世界市場は、2022年に7億8,000万米ドルに達し、2023～2030年の予測期間中にCAGR 4.4％で成長し、2030年には11億米ドルに達すると予測されています。

てんかん患者の3分の1は薬剤耐性の影響を受けていると考えられていますが、その頻度は、てんかん症候群、根本的な原因、発作の初発年齢や併発する神経障害の有無などの要素によって異なります。

薬物抵抗性てんかんは、どのような治療にも不応であるということとは異なるとしても、過去に不成功に終わった治療の回数が増えるにつれて、新しく試験された薬で発作のない状態を確立できる可能性は低くなります。2種類の抗てんかん薬を十分に投与しても発作を抑制できない場合は、可能な限り総合てんかんセンターに転院し、標的治療と診断的再評価を受けるべきです。

ダイナミクス

薬剤耐性てんかん患者の増加

薬剤耐性はてんかん患者の約3分の1を占め、その80％は貧困国に居住しています。薬剤耐性を有する患者は、心理社会的、精神的、医学的な病的状態に陥る可能性が高く、QOLを向上させるためには早急に治療を行う必要があります。薬剤耐性てんかんによる衰弱症状を回避するためには、薬剤耐性てんかんの早期発見が最適な治療法の選択に不可欠です。

てんかんは、最も一般的で、かつ無力化する慢性神経疾患のひとつであり、世界中で6,000万人が罹患し、毎年12万5,000人が死亡しています。てんかんのほとんどの症例において、抗てんかん薬（ASM）は発作の軽減に有効ですが、30～40％の患者は治療抵抗性を示します。

治療法の進歩

ここ数十年の間に、大きな進歩が成し遂げられました。低侵襲手術については、私たちは本当に熱狂しています。このパラダイムシフト的な方法は、開頭手術に代わって、薬剤抵抗性のてんかん患者にとって安全で効率的な選択肢となるかもしれません。VNS、RNS、DBSを用いた神経調節療法も急速に発展しています。

シカゴ大学医療センターでは、これらの装置をさまざまな患者、特に再建手術の適応とならない患者に対して、どのように使用するのが最も効果的かについて、現在も経験を積んでいるところです。CBDオイルは、他のてんかん治療薬と併用することで、まったく別の発作治療薬となり、薬剤抵抗性てんかんの治療に有望視される可能性があります。

ニューロイメージングの進歩

ニューロイメージングの革新は神経科学の領域を一変させ、てんかん、アルツハイマー病、脳卒中、外傷性脳損傷の特定と治療方法、およびこれらの疾患の理解方法に大きな影響を与えました。これらの技術の使用により、研究者や医療従事者は、脳の構造と機能を深く理解することで、患者をより正確に診断し、個人に合わせた治療方針を立てることができます。

高度な画像解析アルゴリズムや機械学習アプローチの開発により、神経画像データにおける問題の自動検出が向上し、早期診断や治療計画の立案に役立っています。

啓発と教育

てんかんや、薬剤耐性てんかんを含むそのサブカテゴリーなど、様々な健康問題に取り組み、管理するためには、認知度を高めることが重要なステップとなります。啓発キャンペーンの目的は、てんかんという疾患、その影響、利用可能な治療法、支援にアクセス可能なリソースについて、一般市民、医療専門家、政策立案者に情報を提供することです。

地域社会やヘルスケアシステムがてんかんの病態をより深く認識するようになるにつれ、薬剤耐性てんかん患者に個別化された治療を提供できるてんかん専門クリニックやセンターの必要性が高まる可能性があります。キャンペーンが活発化した結果、てんかんの研究、特に薬剤耐性てんかんの研究を支援するよう政府や組織が説得されるかもしれません。研究への資金提供は、より効率的な治療法の創出を促すことができます。

限られた治療選択肢

患者やヘルスケア専門家にとって、薬剤耐性てんかんのような一部の医学的疾患に対する限られた治療選択肢は、深刻な困難をもたらす可能性があります。薬剤耐性てんかんは、従来の抗てんかん薬（AED）が効かない病気です。有効な治療法がないために発作が持続し、QOLに悪影響を及ぼし、仕事や運転、日常生活に支障をきたすことがあります。

薬剤耐性てんかんは、不安、悲しみ、社会的孤立、無力感などの心理社会的困難を引き起こす可能性があります。薬剤抵抗性てんかんの患者さんにとって、発作がコントロールできないことは、災難、傷、安全上の問題につながる可能性があります。

個人差

個人のばらつきは、しばしば個人間ばらつきと呼ばれ、治療、薬物、介入に対する反応だけでなく、人々が健康状態をどのように経験し、管理するかのばらつきを表します。この予測不可能性はヘルスケアの重要な要素であり、患者のケア、診断、治療計画に大きな影響を与えます。個人差の重要な要因は遺伝です。

遺伝子の変異は、薬物の代謝能力、治療に対する反応性、特定の医学的障害に対する感受性に影響を与える可能性があります。各人の疾患は、それぞれ独自の方法で発症する可能性があります。治療や予後の決定は、病気の進行のばらつきに影響されます。例えば、がん患者の経験はそれぞれ異なります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 薬剤耐性てんかん患者の増加
      • 治療選択肢の進歩
      • 神経画像診断の進歩
      • 認知度と教育
    • 抑制要因
      • 限られた治療選択肢
      • 個人差
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 治療タイプ別

  • ニューロモデュレーション療法
  • 抗けいれん薬
  • ベンゾジアゼピン系抗てんかん薬
  • てんかん手術療法
  • 特異的代謝治療
  • 特異的遺伝子治療
  • 免疫療法

第8章 エンドユーザー別

  • 病院
  • クリニック
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第11章 企業プロファイル

  • UCB S.A.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Jazz Pharmaceuticals
  • LivaNova PLC：
  • NeuroPace, Inc
  • Avenue Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Others

第12章 付録

目次
Product Code: PH6803

Overview

Global Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 and is expected to reach US$ 1.1 billion by 2030, growing with a CAGR of 4.4% during the forecast period 2023-2030.

A third of epileptics are thought to be affected by drug resistance, however the frequency of this condition varies depending on the epilepsy syndrome, the underlying cause, and other elements including the age at which seizures first appear and the presence of concomitant neurological impairments.

The likelihood of establishing seizure freedom on a newly tested medicine reduces with an increasing number of previously unsuccessful treatments, even if drug-resistant epilepsy is not the same as being refractory to any therapeutic treatment. When two adequately administered anti-seizure drugs have failed to control seizures, patients should, whenever possible, be transferred to a comprehensive epilepsy center for targeted care and a diagnostic re-evaluation.

Dynamics

Increasing Patients with Drug Resistant Epilepsy

Drug resistance will affect around a third of epileptic patients, and 80 percent of them live in poor nations. Patients who are drug-resistant are more likely to experience psychosocial, mental, and medical morbidities, which must be treated right away to enhance their quality of life. To avoid the debilitating symptoms of drug-resistant epilepsy, early detection of drug-resistant epilepsy is crucial for optimal therapy selection.

One of the most common and incapacitating chronic neurologic illnesses, epilepsy affects 60 million people worldwide and results in 125,000 fatalities each year. In most cases of epilepsy, antiseizure medications (ASMs) are successful in reducing seizures, however, 30-40% of individuals develop treatment resistance.

Advancements in Treatment Options

In the recent decades, significant progress has been accomplished. About the minimally invasive surgery, we are really enthusiastic. This paradigm-shifting method may replace open brain surgery as the safe and efficient choice for those with drug-resistant epilepsy. The use of VNS, RNS, and DBS for neuromodulation therapy is also developing quickly.

The University of Chicago Medical Center is still developing experience in how these devices might be used most effectively for various patients, especially for those who are not candidates for reconstructive surgery. When combined with other seizure treatments, CBD oil belongs to an entirely separate class of seizure therapy and may show promise for treating drug-resistant epilepsy.

Advancements in Neuroimaging

Neuroimaging innovations have transformed the area of neuroscience and greatly influenced how epilepsy, Alzheimer's disease, stroke, and traumatic brain injury are identified and treated as well as how these disorders are understood. With the use of these technologies, researchers and medical practitioners can more precisely diagnose patients and create personalized treatment regimens by gaining an in-depth understanding of the structure and function of the brain.

The automatic detection of problems in neuroimaging data has improved thanks to the development of advanced image analysis algorithms and machine learning approaches, assisting in early diagnosis and treatment planning.

Awareness and Education

To address and manage a variety of health issues, such as epilepsy and its subcategories including drug-resistant epilepsy, increasing awareness is a crucial step. The goal of awareness campaigns is to inform the general public, medical experts, and policymakers about the condition, its effects, the therapies that are available, and the resources that are accessible to help.

The need for specialized epilepsy clinics and centers that can offer drug-resistant epilepsy patients individualized care may increase as communities and healthcare systems become more aware of the condition. As a result of increased campaigning, governments and organizations may be persuaded to support research into epilepsy, particularly that into drug-resistant epilepsy. The funding of research can encourage the creation of cures and treatments that are more efficient.

Limited Treatment Options

For patients and healthcare professionals, the limited treatment options for some medical diseases, such as drug-resistant epilepsy, can present serious difficulties. Epilepsy cases classified as drug-resistant do not respond to conventional antiepileptic medications (AEDs). Continuous seizures may result from a lack of effective treatment alternatives, which can negatively affect a person's quality of life and interfere with their ability to work, drive, and carry out daily activities.

Drug-resistant epilepsy can cause psychosocial difficulties such as anxiety, sadness, social isolation, and a sense of helplessness. For people with drug-resistant epilepsy, uncontrolled seizures can lead to mishaps, wounds, and safety issues.

Individual Variability

Individual variability, often referred to as interindividual variability, describes the variations in how people experience and manage their health conditions as well as how they respond to treatments, drugs, and interventions. This unpredictability is a key component of healthcare and has a big impact on patient care, diagnosis, and treatment planning. An important contributor to individual variability is genetics.

Gene variations can impact a person's ability to metabolize drugs, respond to treatments, and be susceptible to specific medical disorders. Each person's disease may develop in a unique way. Decisions on treatment and prognosis are impacted by variations in disease progression. For instance, every patient's experience with cancer will be unique.

Segment Analysis

The global drug-resistant epilepsy market is segmented based on treatment type, end-users, and region.

Antiseizure Medications

Approximately 30% of epilepsy patients are drug-resistant, despite the availability of numerous anti-seizure medicines (ASMs). Other non-pharmacological methods are used to treat people with epilepsy (PWE) or people who are drug-resistant, such as reconstructive surgery, vagus nerve stimulation, and dietary therapy.

These ASMs are typically advised in doses of mono-, bi-, or polytherapy depending on the forms of epilepsy diagnosed and the frequency of seizures. As first-generation ASMs, phenytoin (PHT), carbamazepine (CBZ), and sodium valproate (VPA) are frequently used to treat epilepsy.

Geographical Penetration

Advanced Healthcare Infrastructure

North America has been a dominant force in the global drug-resistant epilepsy market. According to estimates, approximately one-third of North American epileptics have drug-resistant types of the disease. There are numerous specialized epilepsy clinics and facilities throughout North America.

Neurologists and epileptologists with experience in identifying and managing drug-resistant epilepsy are employed by these facilities. In order to effectively diagnose and treat the illness, epilepsy centers in North America frequently provide cutting-edge diagnostic methods, such as video EEG monitoring and neuroimaging.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global drug resistant epilepsy market. Outpatient visits and elective procedures were among the usual healthcare services that were affected by the pandemic. Many people with drug-resistant epilepsy depend on routine exams and diagnostic testing to control their disease, yet during the height of the pandemic, these appointments were rescheduled or canceled.

Due to a lack of access to healthcare services, some people may have had delays in acquiring an accurate epilepsy diagnosis or starting treatment. Telehealth services were quickly embraced in order to solve the problems caused by the pandemic. For patients with epilepsy, including those with drug-resistant forms, neurologists and epileptologists have started conducting online consultations.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine could result in population displacement and damage to the healthcare system. For those who are impacted, accessing medical care, particularly epilepsy treatment, may be difficult. Clinical trials that are still in progress and research projects aimed at finding cures for epilepsy might be impacted.

Research interruptions can hinder the creation of novel medicines and postpone the availability of cutting-edge therapeutics for drug-resistant epilepsy. During geopolitical crises, international collaborations in medical research and healthcare may be disrupted or strained. For the purpose of promoting research and enhancing drug-resistant epilepsy treatment options, collaboration is crucial.

By Treatment Type

  • Neuromodulation Therapy
  • Antiseizure Medications
  • Benzodiazepines
  • Resective Epilepsy Surgery
  • Specific Metabolic Treatment
  • Specific Genetic Treatment
  • Immunotherapy

By End-users

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include: UCB S.A., Jazz Pharmaceuticals, LivaNova PLC, NeuroPace, Inc., Avenue Therapeutics, Xenon Pharmaceuticals Inc., and others.

Why Purchase the Report?

  • To visualize the global drug-resistant epilepsy market segmentation based on treatment type, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of drug-resistant epilepsy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global drug resistant epilepsy market report would provide approximately 44 tables, 48 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Treatment Type
  • 3.2. Snippet by End-users
  • 3.3. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Patients with Drug Resistant Epilepsy
      • 4.1.1.2. Advancements in Treatment Options
      • 4.1.1.3. Advancements in Neuroimaging
      • 4.1.1.4. Awareness and Education
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Treatment Options
      • 4.1.2.2. Individual Variability
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Neuromodulation Therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Antiseizure Medications
  • 7.4. Benzodiazepines
  • 7.5. Resective Epilepsy Surgery
  • 7.6. Specific Metabolic Treatment
  • 7.7. Specific Genetic Treatment
  • 7.8. Immunotherapy

8. By End-users

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 8.2. Market Attractiveness Index, By End-users
  • 8.3. Hospitals*
    • 8.3.1. Introduction
    • 8.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.4. Clinics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. UK
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. UCB S.A.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Jazz Pharmaceuticals
  • 11.3. LivaNova PLC:
  • 11.4. NeuroPace, Inc
  • 11.5. Avenue Therapeutics
  • 11.6. Xenon Pharmaceuticals Inc.
  • 11.7. Others

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us